Sep 10, 2019 / 02:00PM GMT
David Ryan Lewis - Morgan Stanley, Research Division - MD
Let's go ahead and get going here. My name is David Lewis, medical device analyst from Morgan Stanley. It's my pleasure to have us here several members of J&J both on the stage with me and in the audience. To my immediate left, obviously, Scott White, who's group company's Chairman, North American Pharmaceuticals; and Peter Lebowitz, who's Global Therapeutic Head of Oncology. And we've been to the MDA or the Pharmaceutical Day for Johnson & Johnson. You've seen Peter here the last several years.
But before we get going, we're going to have a statement read by Lesley in the audience on J&J public safe harbor, and then we'll get going.
Lesley Fishman - Johnson & Johnson - Senior Director of IR
Great. Thanks, David. Good morning, everyone. Please note that some statements made today may be considered forward-looking or utilize non-GAAP measures. Please refer to our SEC filings, in particular our 10-K, which discuss the risks and uncertainties around forward-looking statements as well
Johnson & Johnson at Morgan Stanley Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot